Skip to main content

Table 2 Relationship between treatment response and clinicopathological factors

From: High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area

  Treatment response Multi-variates
  CR/PR SD/PD P OR
(95%CI)
P
Age      
   50 15 (68.2%) 7 (31.8%) 0.844 1  
   > 50 26 (74.3%) 9 (25.7%)   0.53 (0.07, 3.65) 0.520
Gender      
   male 39 (70.9%) 16 (29.1%) 1.000 1  
   female 2 (100%) 0 (0%)   Indeterminate 1.000
Tumor Site      
   oral cavity 15 (62.5%) 9 (37.5%) 0.049* 1  
   oropharynx 14 (66.7%) 7 (33.3%)   1.29 (0.21, 7.70) 0.778
   hypopharynx/larynx 12 (100%) 0   Indeterminate 0.998
Stage      
   IVa 10 (100%) 0 (0%) 0.048* 1  
   IVb 31 (66.0%) 16 (34.0%)   Indeterminate 0.998
T stage      
   1/2 6 (100%) 0 (0%) 0.170 1  
   3/4 35 (68.6%) 16 (31.4%)   Indeterminate 0.999
N stage      
   negative 8 (66.7%) 4 (25.0%) 0.732 1  
   positive 33 (73.3%) 12 (26.7%)   0.75 (0.06, 8.54) 0.818
Radiation      
   6000 cGy 14 (70.0%) 6 (30.0%) 1.000 1  
   > 6000 cGy 27 (75.7%) 10 (24.3%)   0.22 (0.02, 2.43) 0.222
Alcohol drinking      
   never 9 (81.8%) 2 (18.2%) 0.710 1 0.120
   yes 32 (69.6%) 14 (30.4%)   0.08 (0.004, 1.89)  
   Smoking      
   never 7 (77.8%) 2 (22.2%) 1.000 1  
   yes 34 (70.8%) 14 (29.2%)   2.97 (0.10, 86.59) 0.526
Betel nuts      
   never 16 (80.0%) 4 (20.0%) 0.491 1  
   yes 25 (67.6%) 12 (32.4%)   0.38 (0.03, 4.55) 0.452
ERCC1      
   low expression 28 (90.3%) 3 (9.7%) 0.002* 1  
   high expression 13 (20.0%) 13 (50.0%)   0.07 (0.009, 055). 0.012*
  1. CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; RTO, radiotherapy; OR, odds ratio; CI, confidence interval